within Pharmacolibrary.Drugs.ATC.A;

model A11CC04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.5e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.14,
    k12             = 5.1,
    k21             = 5.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A11CC04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Calcitriol is the hormonally active form of vitamin D3 (1,25-dihydroxycholecalciferol), used in the management of hypocalcemia and bone disorders associated with chronic renal failure, hypoparathyroidism, and some other conditions. It is approved and commonly used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics of calcitriol in healthy adult volunteers following single intravenous dose administration.</p><h4>References</h4><ol><li><p>Levine, BS, &amp; Song, M (1996). Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. <i>Journal of the American Society of Nephrology : JASN</i> 7(3) 488–496. DOI:<a href=\"https://doi.org/10.1681/ASN.V73488\">10.1681/ASN.V73488</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8704116/\">https://pubmed.ncbi.nlm.nih.gov/8704116</a></p></li><li><p>Muindi, JR, et al., &amp; Fakih, MG (2009). A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 65(1) 33–40. DOI:<a href=\"https://doi.org/10.1007/s00280-009-1000-2\">10.1007/s00280-009-1000-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19396601/\">https://pubmed.ncbi.nlm.nih.gov/19396601</a></p></li><li><p>Muindi, JR, et al., &amp; Trump, DL (2002). Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. <i>Clinical pharmacology and therapeutics</i> 72(6) 648–659. DOI:<a href=\"https://doi.org/10.1067/mcp.2002.129305\">10.1067/mcp.2002.129305</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12496746/\">https://pubmed.ncbi.nlm.nih.gov/12496746</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A11CC04;
